Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486067 · ClinicalTrials.gov registry record · Phase 1
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
NCT03486067 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 183 participants.
The verdict
NCT03486067, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
Study Summary
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Interventions
- DRUG CC-93269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486067
The ClinicalTrials.gov registry entry for NCT03486067 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-93269 is the first listed.
NCT03486067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486067 about?
NCT03486067 is a clinical study titled "Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma". Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
What is the current status of trial NCT03486067?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2018-04-03. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT03486067?
The interventions under investigation include: CC-93269 (DRUG).
Who is sponsoring clinical trial NCT03486067?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.